WuXi Biologics Achieves Prestigious MSCI ESG AAA Rating for Fourth Year Running

WuXi Biologics Maintains MSCI ESG AAA Rating

In a notable achievement for sustainability, WuXi Biologics (2269.HK), a prominent player in the Contract Research, Development, and Manufacturing Organization (CRDMO) arena, has confirmed its commitment to environmental, social, and governance (ESG) excellence. On July 8, 2026, the company proudly announced that it has achieved the MSCI's highest AAA ESG rating for the fourth consecutive year and secured a spot in the MSCI 2026 Selection Indexes.

This accomplishment underscores WuXi Biologics' robust dedication to sustainability within the biopharmaceutical sector and highlights its recognized leadership on a global scale. The company’s performance was evaluated across pivotal ESG criteria, such as product safety and quality, human capital development, corporate governance, and addressing climate change—topics that are increasingly important in today’s business landscape.

Dr. Chris Chen, CEO of WuXi Biologics and chairman of the ESG Committee, expressed pride in this achievement, stating, "We are honored to have once again attained MSCI's highest AAA rating. This recognition validates our sustained efforts and continuous improvements in sustainability. As a global leader in Green CRDMO practices, we provide our clients with the tools to meet their own ESG commitments while engaging all stakeholders in promoting responsible practices across the value chain."

The latest rating is particularly significant, achieved under MSCI's Model 5.0—a major revision to the assessment system launched in 2026. This updated model induced changes in ratings for about 37% of the rated issuers. WuXi Biologics' ability to retain its AAA rating demonstrates the resilience and adaptability of its ESG management practices.

The MSCI Selection Indexes serve to spotlight companies that excel in ESG ratings compared to peers, providing critical insights for institutional investors who prioritize sustainability in their investment strategies. The ETFs associated with the MSCI Sustainability and Climate Change indexes rank among the top globally, further affirming the importance of strong ESG performance in investment decisions.

Over the years, WuXi Biologics has garnered significant recognition for its unwavering commitment to sustainable practices. This includes accolades from various esteemed global ESG rating agencies and organizations, such as the EcoVadis Platinum Medal, listings in the Dow Jones World Index, and the FTSE4Good Index Series. Such recognitions underscore the company’s holistic approach to sustainability that encompasses environmental stewardship, social responsibility, and robust corporate governance.

WuXi Biologics, with over 13,000 employees in key markets including the USA, China, and Europe, leverages cutting-edge technologies and profound scientific expertise to deliver efficient and scalable biologic solutions to clients across the globe. The company is dedicated not just to driving profits but to creating shared value through innovation and responsible business practices.

The strategic integration of digital capabilities within its operations ensures that WuXi Biologics can swiftly respond to client needs while maintaining transparency and operational intelligence. Currently, WuXi is supporting a portfolio of 982 integrated projects, showcasing its capacity to handle complexity and scale in biologic manufacturing effectively.

WuXi Biologics regards sustainability as foundational to its long-term growth strategy. Its commitment translates into continuous technological advancements and collaborative efforts with stakeholders aimed at facilitating positive social and environmental impacts. By delivering on its promise of responsible practices, WuXi Biologics aspires to not only be a leader in the CRDMO field but also a catalyst for positive change in global health.

To learn more about WuXi Biologics' offerings and its commitment to sustainability, visit www.wuxibiologics.com.